- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Eisai submits regulatory applications for eribulin in the US, EU and Japan
31 July 2015 • Author: Victoria White
Eisai has submitted regulatory applications in the United States, European Union and Japan for eribulin for the treatment of patients with inoperable soft tissue sarcoma (STS) who have received prior chemotherapy for advanced or metastatic disease.
These regulatory filings are based on data from a pivotal global Phase 3 clinical trial (Study 309) which met its primary endpoint evaluating overall survival in patients previously treated for soft tissue sarcoma. Study 309 is the first and only study to meet an overall survival endpoint at this stage of the disease.
“Soft tissue sarcomas can be challenging to treat and there remains a substantial unmet medical need for patients who fail to respond to treatment, and therefore have a poor prognosis,” said Patrick Schöffski, MD, MPH, Department of General Medical Oncology, University Hospitals Leuven, Belgium. “Physicians have long sought additional therapies that have the potential to improve overall survival for patients with STS.”
Approval of eribulin for STS will represent an important milestone for physicians and patients
Study 309 was a randomised, open-label, multicentre trial of eribulin mesylate administered intravenously (IV) on days one and eight of a 21-day cycle versus dacarbazine IV on day one, every 21 days to patients with locally advanced or recurrent and/or metastatic leiomyosarcoma or liposarcoma who had disease progression following two standard therapies, one of which must have been an anthracycline (unless contraindicated).
“These regulatory submissions signify the potential for an additional treatment option for patients with this difficult-to-treat disease, an important milestone for physicians and patients,” said Kenichi Nomoto, President, Oncology Product Creation Unit, Eisai Product Creation Systems. “The investigation of eribulin in STS underscores Eisai’s human health care mission, the company’s steadfast commitment to innovative solutions in the treatment of diseases and care for the health and well-being of people worldwide.”
Eribulin is approved for patients with metastatic breast cancer who have received at least two chemotherapeutic regimens for the treatment of metastatic disease, and whose prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics